ImmunoGen, Inc.

Website Links

Description

David Johnston joined ImmunoGen in December 2013 as EVP and CFO bringing to ImmunoGen more than 30 years of experience in corporate finance, including 15 years in senior financial functions at biotechnology companies, as well as extensive experience in corporate planning. Prior to joining ImmunoGen, Mr. Johnston was chief financial officer at AVEO Pharmaceuticals Inc. Prior to joining AVEO in 2007, he was Senior Vice President of Finance, Corporate Planning and Analysis at Genzyme Corporation and, before that, the VP Finance and CFO of Genzyme Biosurgery. Prior to joining Genzyme in 1998, Mr.

We use our antibody-drug conjugate (ADC) technology – together with our strong antibody expertise – to develop our own product candidates. We currently have three wholly owned clinical-stage compounds – IMGN853 , IMGN529 and IMGN289 . We continue to invest in our ADC technology to maintain our leadership position. We also selectively outlicense our technology to other companies for use with their engineered antibodies. We have partnerships with Amgen, Bayer, Biotest, Lilly, Novartis, Roche and Sanofi – all of which have clinical and/or preclinical compounds utilizing our technology.

Craig Barrows joined ImmunoGen in October 2007 with over twenty years of legal experience – thirteen as chief corporate legal officer – and a strong transactional background. Mr. Barrows was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Most recently, Mr.

This web site includes links to other web sites. We provide these links as a convenience for you, and our inclusion of a link does not imply an endorsement of that web site. ImmunoGen has no control over the content on those web sites, and we do not take any responsibility or assume any liability for information contained on third party web sites. You use the links to those web sites at your own risk and you are responsible for learning about and complying with the terms of usage and other conditions posted on those web sites.

Dr. Morris joined ImmunoGen in November 2012 bringing nearly twenty years of experience in the development of anticancer compounds, including experience with registration clinical trials, regulatory approvals, pharmacovigilance, and medical affairs support for marketed products. Prior to joining ImmunoGen, he was the executive vice president and chief medical officer at Allos Therapeutics, Inc., where he led the company's clinical development functions including clinical operations, regulatory, and pharmacovigilance. Prior to joining Allos in 2010, Dr.

Products & services

Similar companies nearby